What is HC Wainwright's Estimate for ABEO FY2024 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Research analysts at HC Wainwright boosted their FY2024 earnings estimates for Abeona Therapeutics in a research report issued to clients and investors on Monday, November 25th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of ($1.16) for the year, up from their prior forecast of ($1.26). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.17) EPS.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. StockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th.

Abeona Therapeutics Price Performance

Shares of NASDAQ ABEO traded up $0.38 during mid-day trading on Wednesday, hitting $6.41. 719,016 shares of the stock traded hands, compared to its average volume of 430,801. The company has a market cap of $278.64 million, a PE ratio of -2.39 and a beta of 1.52. Abeona Therapeutics has a twelve month low of $3.05 and a twelve month high of $9.01. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a 50 day simple moving average of $6.22 and a two-hundred day simple moving average of $5.32.

Institutional Investors Weigh In On Abeona Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its holdings in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock worth $515,000 after purchasing an additional 2,434 shares during the period. Acadian Asset Management LLC acquired a new stake in Abeona Therapeutics in the first quarter valued at approximately $91,000. Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $84,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Abeona Therapeutics during the third quarter worth approximately $151,000. Finally, XTX Topco Ltd acquired a new position in shares of Abeona Therapeutics during the third quarter worth approximately $160,000. Institutional investors and hedge funds own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.